Posted: 09-18-10 Categories:
Avandia FDA
Avandia News
Avandia Safety

FDA reviewing safety of Avandia’s rival diabetes drug Actos

The attorneys at no longer are accepting new Avandia cases.

The FDA announced yesterday [9-17-2010] that it has begun reviewing the safety of the diabetes drug Actos (pioglitazone), after receiving early results from research to evaluate drug’s bladder cancer risk.

Actos sales have soared in recent years since use rival diabetes drug Avandia was linked to increased risks of heart attack, stroke, acute congestive heart failure and heart related death. Earlier this year, 12 of 32 members of a FDA joint drug safety advisory committee called for an Avandia recall.

The FDA has not concluded that Actos increases the risk of bladder cancer. However, 5-year data from a 10-year study demonstrated an increased risk of bladder cancer in patients with the longest exposure and in those having taken the highest cumulative dose of Actos.

Actos and Avandia (rosiglitazone) both belong to a class of diabetes drugs known as peroxisome proliferator-activated receptor (PPAR) agonists. The FDA has no clinical information associating Avandia with bladder cancer in patients receiving that drug.

For more information:

Ongoing Safety Review of Actos (pioglitazone) and Increased Risk of Bladder Cancer

The attorneys at no longer are accepting new Avandia cases.

Recent Comments
  • SEABEECH: Peace be with you. My dad died at 11:22 on December 21, 201...
  • vertee jackson jr: The company hired to save (GSK) money is using a point syste...
  • E. Tan: I am from the Philippines and my mother, a diabetic for more...
  • A. Held: "Documents released earlier this year by the Senate Finance ...
  • Robert: I was 37 and had to have Quadruple bypass in Oct 2005. I was...